Cision Vision

Cision Vision is a medical technology company specializing in shortwave infrared (SWIR) imaging systems for pathology and surgical applications. Founded in 2020 as an MIT spinoff, the company's flagship InVision device provides label-free, real-time imaging that enhances lymph node identification and tissue grossing in laboratory and intraoperative settings. The technology leverages SWIR wavelengths (1000–2000 nm) to penetrate biological tissues deeply and provide natural contrast based on water and lipid content, eliminating the need for contrast agents or radiation. InVision has been recognized as one of Time Magazine's Best Inventions of 2023 and is deployed across multiple U.S. hospitals. The company's surgical application focuses on AI-powered critical structure identification during intraoperative guidance. Cision Vision has received significant government funding, including a prestigious ARPA-H award of up to $22.3 million as part of the Biden Cancer Moonshot initiative. The company collaborates with leading institutions including Johns Hopkins Medicine and Stanford Medicine, and operates the Visionary Program to support early-access initiatives for pathology innovators. Clinical validation includes a multicenter study published in the Journal of Clinical Pathology.